About Biocon Our Business Research & Development Biocon's Technology Investors Media Careers CSR
  > INVESTORS
  Overview
  Corporate Structure
  Corporate Governance
  Company History
  Annual General Meeting
  Postal Ballot
  Investor FAQs
  Stock Info
  Financial Results
  Subsidiary Financials
  Annual Report
  Disclosure to Stock Exchange
  Nomination form
  Press Releases
  Presentations
  Analyst Coverage
  Investor Contacts
  
  
     
 
Disclosure to Stock Exchange

  December 2017
29 Dec

Biocon and Mylanís Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through Their Partner Libbs

Download Pdf
22 Dec

Intimation of Board Meeting

Download Pdf
21 Dec

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
20 Dec

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
19 Dec

Intimation Regarding Analysts / Institutional Investors Meet

 

Download Pdf
15 Dec

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
14 Dec

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
13 Dec

Biocon’s Clarification post media reports on “Biocon on the FDA list for not paying facility fee”

Download Pdf
07 Dec

Intimation Regarding Analysts / Institutional Investors Meet

 

Download Pdf
07 Dec

Results of Postal Ballot / eVoting

Download Pdf
07 Dec

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
05 Dec

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
01 Dec

U.S. FDA Approves Mylan and Biocon´s OgivriTM the First Biosimilar for Trastuzumab, for the Treatment of HER2­Positive Breast and Gastric Cancers

 

Download Pdf
01 Dec

European Medicines Agency Accepts Marketing Authorization Applications for Mylan and Biocon´s Proposed Biosimilars Trastuzumab and Pegfilgrastim

 

Download Pdf
  November 2017
23 Nov

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
23 Nov

Biocon Launches KRABEVA® − Biosimilar Bevacizumab for Treating Several Types of Cancer in India

Download Pdf
20 Nov

Biocon's Facility Receives EIR with VAI status, Inspection Closed

Download Pdf
15 Nov

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
14 Nov

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
10 Nov

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
08 Nov

Presentation on financial results of the Company for the quarter and half year ended September 30, 2017

Download Pdf
06 Nov

Resubmission of Biosimilar Trastuzumab and Pegfilgrastim Dossiers with EMA

Download Pdf
06 Nov

Postal Ballot Advertisement

Download Pdf
03 Nov

Postal Ballot Notice to Shareholders

Download Pdf
  October 2017
30 Oct

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
27 Oct

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
25 Oct

Biocon Ranked Among Top 10 Global Pharma & Biotech Employers

Download Pdf
10 Oct

US FDA Issues Complete Response Letter for Proposed Biosimilar Pegfilgrastim

Download Pdf
  September 2017
27 Sept

Intimation of Board Meeting

Download Pdf
21 Sept

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
19 Sept

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
18 Sept

Bioconís Facility in Vishakhapatnam completes US FDA Inspection with no observations

Download Pdf
15 Sept

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
8 Sept

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
7 Sept

Biocon´s Insulins facility in Malaysia Receives EU GMP Compliance Certificate

Download Pdf
6 Sept

JDRF Supports Biocon Study of Novel, Fast-acting Oral Insulin Tregopil for Type 1 Diabetes Treatment

Download Pdf
5 Sept

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
  August 2017
30 Aug

USFDA Target Action Date for Trastuzumab Reset to December 3, 2017

Download Pdf
29 Aug

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
23 Aug

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
22 Aug

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
17 Aug

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
16 Aug Company Statement on Status of EMA Dossiers Download Pdf
11 Aug Incorporation of WOS Download Pdf
07 Aug Intimation Regarding Analysts / Institutional Investors Meet Download Pdf
  July 2017
31 Jul Company Statement on USFDA Visit in May/June2017. CAPA is under Implementation Download Pdf
31 Jul Intimation Regarding Analysts / Institutional Investors Meet Download Pdf
14 Jul Press Release titled "FDA Oncologic Drugs Advisory Committee Unanimously Recommends Approval of Mylan and Bioconís Proposed Biosimilar Trastuzumab" Download Pdf
09 Jul Company's Statement on the outcome of pre-approval inspection audits by French health agency, L'Agence nationale de securite du medicament et des produits de sante (ANSM) on behalf of European Medicines Agency (EMA) Download Pdf
  June 2017
23 Jun Intimation Regarding Analysts / Institutional Investors Meet Download Pdf
20 Jun Intimation Regarding Analysts / Institutional Investors Meet Download Pdf
11 Jun Press Release titled "Mylan and Biocon Present Clinical Data on Insulin Glargine at the American Diabetes Association's 77th Scientific Sessions" Download Pdf
1 Jun Intimation Regarding Analysts / Institutional Investors Meet Download Pdf
  May 2017
11 May Intimation Regarding Analysts / Institutional Investors Meet Download Pdf
10 May Biocon Statement in response to Media Reports on USFDA Form 483s for Biocon Limited. Download Pdf
08 May Newspaper Advertisement For Dispatch Of Postal Ballot Notice And Postal Ballot Form. Download Pdf
05 May Notice Of Postal Ballot Download Pdf
  April 2017
28 Apr Intimation regarding Analyst / Institutional Investor Meet Download Pdf
28 Apr Presentation - Analysts/Institutional Investors Meet Download Pdf
27 Apr  Outcome of Board Meeting Download Pdf
  March 2017
30 Mar  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
27 Mar  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
15 Mar  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
06 Mar  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
03 Mar  Biocon's statement in response to Delhi  High Court Interim Order Download Pdf
02 Mar  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
  February 2017
27 Feb  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
24 Feb  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
22 Feb  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
16 Feb  USFDA accepts Biologics License Application  (BLA) for Mylan and Biocon's proposed  Biosimilar Pegfilgrastim for Review Download Pdf
14 Feb  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
07 Feb  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
  January 2017
30 Jan  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
24 Jan  Biocon Q3 FY17 Net Profit Up 65% at Rs 171  Crore; Revenue Rises 32% at Rs 1092  Crore; EBITDA Increases 57% to Rs 324  Crore Download Pdf
11 Jan  U.S. FDA Accepts Biologics License  Application (BLA) for Mylan and Biocon's  Proposed Biosimilar Trastuzumab Download Pdf

 
     
 January to June 2020
 January to December 2019
 January to December 2018
 January to December 2017
 January to December 2016
 December 2015
 
 
     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer            © 2018, Biocon. All Rights Reserved